-
Article
Open AccessPrevious radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
Immune-related adverse events (irAEs) are frequently encountered by patients during immune checkpoint inhibitor (ICI) treatment and are associated with better treatment outcomes. The sequencing of radiotherapy...
-
Article
Open AccessEvolution and modulation of antigen-specific T cell responses in melanoma patients
Analyzing antigen-specific T cell responses at scale has been challenging. Here, we analyze three types of T cell receptor (TCR) repertoire data (antigen-specific TCRs, TCR-repertoire, and single-cell RNA + TC...
-
Article
Open AccessAge-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-...
-
Article
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
Matrix metalloproteinases (MMPs) are important enzymes in tissue turnover and various inflammatory processes. In this study, it was evaluated whether serum MMP-8 can predict the response to adjuvant interfero...
-
Article
Open AccessNivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
-
Article
Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy
Immunogenic features of some malignancies have aroused interest in immunotherapy of cancer. Immunotherapy seems most effective in patients with a small tumour burden, and the focus of immunotherapy trials has,...
